Summary
Core view: Neuland's Q1 FY27 total income rose 116% year-on-year and PAT rose over 9x, driven by both its Custom Manufacturing Solutions (CDMO) and Generic Drug Synthesis businesses. However, both revenue and PAT fell sharply quarter-on-quarter from an exceptionally strong Q4 FY26, underlining that CDMO milestone and batch timing can make quarterly results lumpy even as the multi-year trend improves.
Neuland is a CDMO and generic-API company serving global innovator and generic pharma customers. Its CMS (custom manufacturing/CDMO) segment carries project- and milestone-linked revenue that can vary sharply by quarter, while GDS provides a steadier generic-API base.
Q1 FY27 Snapshot
Total income₹650.1 Cr+116.3% YoY, -17.6% QoQ
EBITDA₹231.1 CrMargin 35.5%
PAT₹147.7 Cr+962% YoY, -30.6% QoQ
EPS (Q1)₹114.9-115.1Down from Q4 FY26
| Metric | Q4 FY26 | Q1 FY27 |
|---|---|---|
| Operating margin | 39.6% | 34.7% |
| Total income | Higher (sequential decline of 17.6%) | ₹650.1 Cr |
| PAT | Higher (sequential decline of 30.6%) | ₹147.7 Cr |
Business Quality And Mix
Strengths
- CMS (CDMO) and GDS businesses both grew strongly year-on-year.
- 35.5% EBITDA margin is high for a CDMO/API business.
- Long track record of regulated-market API supply.
- Management guides to about 20% annual growth for FY27-FY28.
Constraints
- Sequential decline from Q4 FY26 shows CDMO milestone timing can be lumpy.
- High capex intensity to support CMS capacity.
- Customer/project concentration typical of CDMO businesses.
- Very high per-share price limits retail accessibility (small share count).
Growth Drivers And Capacity Economics
Management guidance~20% annual growthFY27-FY28
EBITDA margin35.5%Q1 FY27
Shares outstanding~1.28 CrSmall float
Growth is being driven by both CMS/CDMO project wins and steady GDS generic-API demand. Capex remains elevated to support CDMO capacity, which management expects to convert into sustained double-digit growth over FY27-FY28.
Management Guardrails And Credibility
| Objective | Target | Assessment |
|---|---|---|
| Revenue growth | ~20% annually for FY27 and FY28 | Management-stated expectation, per the cited Q1 FY27 commentary. |
| Margin | Maintain a mid-30s% EBITDA margin over the cycle | Q1 FY27's 34.7% operating margin is within this range, though down from Q4 FY26's 39.6%. |
| Capex | Continued investment in CDMO capacity | Necessary to support the growth guidance, with associated execution and utilisation risk. |
Financial Quality
EBITDA margin35.5%Q1 FY27
Sequential PAT change-30.6% QoQOff an exceptional Q4 base
YoY PAT change+962%Off a weak Q1 FY26 base
Shares outstanding~1.28 CrHigh per-share price
| Quality test | Reading | Interpretation |
|---|---|---|
| Earnings quality | PAT +962% YoY but -30.6% QoQ | The YoY comparison is flattered by a weak prior-year base; the QoQ decline shows CDMO milestone lumpiness. |
| Margin trend | 34.7% operating margin vs 39.6% in Q4 FY26 | Some margin normalization from an exceptional prior quarter is expected in a CDMO-heavy mix. |
| Growth durability | Management guides ~20% annual growth | Reasonable if CMS project wins continue, but individual quarters should not be extrapolated. |
Valuation
Key Risks
- CDMO milestone and project timing lumpiness.
- Customer/project concentration typical of CDMO.
- High capex intensity for CMS capacity.
- Very high per-share price and small float can raise volatility.
- Margin normalization from the Q4 FY26 peak.
Projection: Next 2-4 Quarters
Investor Watchlist
- CMS vs GDS revenue mix each quarter.
- Operating margin trend versus the 34.7-39.6% recent range.
- Progress against the ~20% annual growth guidance.
- Capex and capacity utilisation.
- Customer concentration disclosures, if provided.